These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33563660)

  • 1. A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function.
    Lange S; Sand LGL; Bell M; Patil SL; Langfitt D; Gottschalk S
    Cancer Discov; 2021 Jul; 11(7):1661-1671. PubMed ID: 33563660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
    Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
    Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.
    Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J
    Mol Ther; 2024 Jul; 32(7):2373-2392. PubMed ID: 38745414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
    Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
    Clin Cancer Res; 2024 Aug; 30(16):3564-3577. PubMed ID: 38593230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 7. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
    Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
    J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Du X; Darcy PK; Wiede F; Tiganis T
    Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
    Sterner RM; Cox MJ; Sakemura R; Kenderian SS
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 13. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
    Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W
    FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 18. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
    Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
    Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
    Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
    Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
    Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
    J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.